A2aR KO/KD resulted in decreased tumor size and enhanced anti-tumor killing abilities of CAR T cells compared to controls in five studies in subjects with breast, colon, pancreatic, cervical, and ovarian carcinoma [102, 107, 114, 120, 184]. Here, ADORA2A is linked to ovarian carcinoma.